Epiprobe’s pan-cancer biomarker followed Siemens Healthcare’s “Angel Project” into Wuwei

The “Angel Project” assists precision medical poverty alleviation.

On February 19, 2023, the Central Committee of the Chinese People’s Political Consultative Conference (CPPCC) and Siemens jointly launched the Guardian Angel Project in Gansu Province, donating advanced equipment and providing high-quality medical instruments to the local area. The project has played an important role in effectively filling the gaps in diagnostic and treatment equipment and technology at the grassroots level of county-level medical institutions, improving the diagnosis and treatment capabilities of primary medical institutions, alleviating difficulties in seeking medical treatment for the public.

Medical training classes have been opened with the aim of further improving the medical technician team and their technical level, as well as enhancing the ability of medical workers to treat and save lives. In the next step, a series of training programs to enhance medical management and diagnosis and treatment capabilities will be carried out throughout the province. Epiprobe has followed the “Angel Project” into Wuwei, providing new technology for cancer detection with full cancer markers to serve the local people and contribute to the development of the medical and health care industry.

Epiprobe followed the “Angel Project” into Wuwei.

Wuwei is located in the central part of Gansu Province in northwestern China and has a long history. It is known as a national historical and cultural city. However, despite its rich history, the level of medical care in the area is relatively backward. In order to improve the local medical standards and protect the health of the local people, Epiprobe followed Siemens Medical and the Chinese People’s Political Consultative Conference’s “Angel Project” into Wuwei, providing methylation detection services.

In order to improve the cancer detection level of hospitals in Wuwei, Epiprobe actively cooperated with local hospitals to provide methylation detection technology training, offering local doctors a new method for earlier, more accurate, and more effective cancer screening.

Pan-cancer marker TAGMe® escorts local women’s health.

The incidence of reproductive system cancers in women is severe. Approximately 140,000 new cases of cervical cancer and 80,000 new cases of endometrial cancer are diagnosed each year, ranking first and second respectively in reproductive system cancers. Due to limitations in detection methods, most cases of cervical and endometrial cancer are diagnosed in the advanced stages.

According to research statistics, the five-year survival rate for advanced-stage cervical cancer is only 40%. If the diagnosis can be made in the pre-cancerous stage, the cure rate can reach 100%, truly achieving the goal of eliminating cervical cancer and saving more lives.

To help women in Wuwei prevent and control cervical and endometrial cancer, Epiprobe followed Siemens Healthcare and the Democratic League’s “Angel Project” to Wuwei, bringing methylation detection technology to protect the health of local women.

Epiprobe has developed a unique pan-cancer biomarker, TAGMe, and a Me-qPCR platform that does not require metabisulfite treatment, to develop TAGMe DNA Methylation Detection Kits for female reproductive tract cancer. Its comprehensive application scenarios can help more women avoid the threat of cervical and endometrial cancer.

Scenario 1: Early screening of cancers (early detection of pre-cancerous lesions)

Scenario 2: High-risk HPV population triage

Scenario 3: Auxiliary diagnosis of suspicious populations

Scenario 4: Risk assessment of residual lesions after surgery

Scenario 5: Postoperative population recurrence monitoring

Epiprobe is committed to love and follows the “Angel Project”. Starting from Wuwei station, it spreads health care to more people.

Post time: May-04-2023